| Title | Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. | | Author(s) | Markman M, Liu PY, Rothenberg ML, Monk BJ, Brady M, Alberts DS | | Institution | M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA. mmarkman@mdanderson.org | | Source | J Clin Oncol 2006 Mar 20; 24(9):1454-8. | | MeSH | Aged
Altretamine
Antineoplastic Combined Chemotherapy Protocols
CA-125 Antigen
Disease Progression
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Ovarian Neoplasms
Paclitaxel
Predictive Value of Tests
Research Support, N.I.H., Extramural
Retrospective Studies
Survival Analysis
| | Abstract | PURPOSE: A previous report suggested the nadir serum CA-125 level within the group of patients with ovarian cancer who achieved normalization of CA-125 accurately defined the risk of relapse. Using similar CA-125 subgroups, we sought to determine if the baseline CA-125 level before initiation of maintenance chemotherapy in women achieving a clinically-defined complete response to primary chemotherapy would be of prognostic value.
PATIENTS AND METHODS: Patients included in this retrospective analysis had been treated on one of two previously reported trials of maintenance chemotherapy (three v 12-monthly cycles of paclitaxel; oral altretamine), with a baseline CA-125 level of < or = 35 u/mL. Progression-free survival (PFS) from study entry was analyzed by the Cox regression model.
RESULTS: The distribution of premaintenance baseline CA-125 levels for the 384 patients was 58%, 34%, and 8% for values of (A) < or = 10 u/mL, (B) 11 to 20 u/mL, and (C) 21 to 35 u/mL, respectively. The baseline CA-125 was highly statistically significant, either as a categoric variable (P < .001) or as a continuous variable (P < .0001). Median PFS was 24 months, 17 months, and 7 months for groups (A), (B), and (C), respectively. There was no evidence the CA-125 effect differed by trial or treatment in an interaction analysis (P = .70).
CONCLUSION: The baseline CA-125 level before initiation of maintenance chemotherapy strongly predicts the risk of subsequent relapse. Patients with premaintenance baseline CA-125 values < or = 10 u/mL have a superior PFS compared with higher levels in the normal CA-125 range. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 16549840 |
|
